


Edwards Lifesciences



2025 Corporate Impact Highlights

At Edwards, helping patients is our purpose and guides every decision we make. We're proud that our greatest impact lies in addressing unmet needs and making a meaningful difference for patients, society, and the stakeholders we serve.

This commitment is brought to life through our comprehensive environmental, social, and governance practices. Around the world, we see the impact of these efforts each day, driven by a shared passion for helping patients and realized through the dedication of our teams.

Together, we are making a difference.

PATIENTS FIRST Helping patients is our life's work and life is now.

3.5 Million lives improved

Edwards and Edwards Foundation's Every Heartbeat Matters community of partners surpassed its 2.5 million 2025 milestone goal by improving the lives of 3.5 million underserved patients since 2020



1 Million+ patients treated

More than 1 million patients treated with Edwards' transcatheter technologies



1 Billion+ invested in R&D

(17.8% of sales)



10,000+ patents



Received FDA and CE Mark approval for the SAPIEN M3 mitral valve replacement system, the first transeptal transcatheter therapy for patients with symptomatic mitral regurgitation who are not candidates for surgery or edge to edge repair



American Heart Association.

Founding sponsorship of the American Heart Association's Heart Valve Initiative, a national effort to improve care and outcomes for more than 28 million people living with heart valve disease worldwide



OUR PRODUCTS

Delivery of high-quality products is key to our culture, reputation, and business.



Announced new eight-year data showing patients receiving aortic surgical valves made from RESILIA tissue technology showed significantly improved long term outcomes compared to those receiving non-RESILIA bioprosthetic valves



THE PARTNER 3 TRIAL

Announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR

Continuous improvement efforts to **zero** patient safety-related Class I product removals



No

significant disruption of product availability

OUR PEOPLE

Our greatest asset is our highly engaged global team.



100% complete

All global employees completed unconscious bias training, and new hires completed the training within six months of employment

Annual top talent retention resulted in voluntary turnover less than high-performing benchmarks



Highly engaged workforce that exceeded industry, region and high-performing benchmarks for employee engagement



100% complete

All new employees completed Code of Conduct training within 60 days of start date

OUR PLANET

Safe and environmentally responsible operations bring shared value to everyone.

42% Reduction

Reduce absolute Scope 1 and 2 greenhouse gas emissions 42% from a 2021 base year and achieve carbon neutrality by 2030



51.6% Reduction

Reduce Scope 3 greenhouse gas emissions 51.6% per USD of value added from a 2021 base year by 2030

Achieved a 20% absolute reduction in Scope 1 and 2 greenhouse gas emissions over the prior year



Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2026 Edwards Lifesciences Corporation. All rights reserved.

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com

